Overview

In light of the COVID-19 pandemic, unanticipated supply chain disruptions and postponed FDA inspections have created significant risks and challenges for the global medical product manufacturing network. The recently enacted CARES Act and new FDA guidance have established a new framework for addressing supply chain disruptions through formal risk management plans. In this webinar, presenters will discuss regulatory requirements as well as strategies for developing a post-Coronavirus recovery action plan, how to implement and manage an effective plan, and how to be prepared for an establishment inspection, whether through record reviews or during on-site inspections post-crisis.

Get Access

$49
  • +$150 for nonmembers

 

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Speakers

Daniel Barreto, President and CEO, PharmQ Global Consulting
Cathy L. Burgess, Partner, Alston & Bird LLP and Member, FDLI Board of Directors
Joseph Jimenez, Managing Director, Arches Consulting, LLC
Moderated by  Robert A. Rhoades, Managing Partner, Validant

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

 

On-demand content can be played back on most devices.

If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements. 

CLE credit is not currently available for pre-recorded sessions.

Related Content